This event will be webcast live. Please see Registration tab for details.
There is no fee to participate in this satellite symposium program or live webcast of this event. However, in order to attend the in-person event you must be registered for the 2021 Pan Pacific Lymphoma Conference.
Faculty Muhamed Baljevic, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Internal Medicine
Fred and Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska
Joseph Mikhael, MD
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
City of Hope Cancer Center
Phoenix, Arizona
Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology Oncology
University of California, San Francisco
San Francisco, California
Consulting Faculty Mamta Choksi, MD
Florida Cancer Specialists and Research Institute
New Port Richey, Florida
Justin Peter Favaro, MD, PhD
Oncology Specialists of Charlotte
Charlotte, North Carolina
Ranju Gupta, MD
Attending Physician
Co-Director, Cardio-Oncology Program
LVPG Hematology Oncology Associates
Lehigh Valley Health Network
Bethlehem, Pennsylvania
Benjamin Parsons, DO
Hematology/Oncology
Gundersen Health System
Madison, Wisconsin
Moderator Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Oncopeptides and Takeda Oncology.
MODULE 1: Up-Front Management of Newly Diagnosed Multiple Myeloma (NDMM) — Dr Orlowski
Comparative efficacy and tolerability of carfilzomib/lenalidomide/dexamethasone (KRd) and lenalidomide/bortezomib/dexamethasone (RVd) in the Phase III ENDURANCE trial; implications for routine practice
Published findings from Phase III trials evaluating daratumumab-containing front-line regimens for NDMM
Updated data from the Phase II GRIFFIN study evaluating RVd/daratumumab in transplant-eligible newly diagnosed MM; recent NCCN guideline inclusion, current nonresearch role and ongoing investigation
Selection of an optimal maintenance approach for transplant-eligible or -ineligible patients
Available data with oral ixazomib in the induction and maintenance settings (TOURMALINE-MM2, MM3 and MM4 trials) and current clinical utility
MODULE 2: Selection and Sequencing of Therapies for Patients with Relapsed/Refractory (R/R) MM — Dr Mikhael
Published Phase III research with isatuximab for R/R MM (eg, ICARIA-MM, IKEMA trials); FDA approval, optimal use in clinical practice and ongoing research
Phase III BOSTON trial and FDA approval of selinexor in combination with bortezomib/dexamethasone for patients with R/R MM who have received at least 1 prior therapy; ongoing investigation of other selinexor combinations
Key efficacy and safety data from the pivotal Phase II HORIZON study of melflufen/dexamethasone for R/R MM leading to FDA approval of this regimen for patients who have received at least 4 prior lines of therapy
Efficacy and safety findings leading to the FDA approval of the BCMA-directed antibody-drug conjugate belantamab mafodotin for patients with R/R MM; incorporation into routine practice
MODULE 3: Chimeric Antigen Receptor (CAR) T-Cell Therapy in MM — Dr Shah
Design, eligibility criteria and updated efficacy and safety results from the pivotal Phase II KarMMa trial evaluating idecabtagene vicleucel (ide-cel) in patients with R/R MM
Recent FDA approval of ide-cel for heavily pretreated MM; optimal timing and selection of patients for treatment
Updated findings from the CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated MM; potential clinical role
Initial results from Cohort A of the CARTITUDE-2 trial investigating cilta-cel after 1 to 3 prior lines of therapy and implications for future research
Early data with and ongoing clinical research efforts evaluating other CAR T-cell platforms in MM
MODULE 4: Novel Agents and Strategies Under Investigation — Dr Baljevic
Biologic rationale for targeting Bcl-2 in MM; favorable risk-benefit ratio and current nonresearch role of venetoclax-based therapy for patients with t(11;14) or Bcl-2 overexpression
Phase III CANOVA trial evaluating venetoclax/dexamethasone versus pomalidomide/dexamethasone for patients with R/R MM with t(11;14); other ongoing studies assessing venetoclax-based combinations
Mechanism of action of cereblon E3 ligase modulators (CELMoDs) (eg, iberdomide, CC-92480) and similarities and differences between CELMoDs and standard immunomodulatory drugs
Activity and safety observed with iberdomide and CC-92480 in patients with heavily pretreated MM
Mechanism of action of and available safety and efficacy data with bispecific antibodies (eg, teclistamab, talquetamab, cevostamab, elranatamab) in R/R MM; future development plans
Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of multiple myeloma (MM).
Learning Objectives
At the conclusion of this activity, participants should be able to
Customize the use of induction, consolidation and maintenance therapeutic approaches for MM in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
Appreciate available clinical trial data informing the use of monoclonal antibody therapy directed at CD38 as a component of front-line treatment for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
Recognize published research data validating minimal residual disease (MRD) status as a predictor of long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in the protocol and nonresearch management of MM.
Consider published research findings and other clinical factors in the best-practice selection, sequencing or combining of established regimens in the care of patients with relapsed/refractory MM.
Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies (eg, isatuximab, selinexor, belantamab mafodotin, melflufen) to facilitate the integration of these agents into MM management algorithms.
Appreciate available data documenting the activity of chimeric antigen receptor T-cell therapy targeting BCMA in MM, and use this knowledge to identify patients who may be appropriate for this approach within or outside of a protocol setting.
Recall the design of ongoing clinical trials evaluating novel agents and therapeutic strategies for MM, and counsel appropriate patients about availability and participation.
Accreditation and Credit Designation Statement
In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS: The University of Nebraska Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES: The University of Nebraska Medical Center designates this activity for 1.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Credit Form
A credit form will be given to each participant.
In order to receive credit, attendees must check in at registration and turn in a completed credit form at the conclusion of the activity. Credit certificates will be issued directly to attendees by UNMC CCE within 4 to 6 weeks after the symposium.
Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.
All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
Disclosures
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:
FACULTY — Muhamed Baljevic, MD — Advisory Boards: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation; Research Support: Amgen Inc, Exelixis Inc. Mamta Choksi, MD – No relevant conflicts of interest to disclose. Justin Peter Favaro, MD, PhD – Advisory Committee: Genentech, a member of the Roche Group, Janssen Biotech Inc, Seagen Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Incyte Corporation, Merck, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Secura Bio Inc. Ranju Gupta, MD – No relevant conflicts of interest to disclose. Joseph Mikhael, MD – Consulting Agreements: Amgen Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Takeda Oncology. Benjamin Parsons, DO – No relevant conflicts of interest to disclose. Nina Shah, MD – Consulting Agreements: Amgen Inc, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Kite, A Gilead Company, Oncopeptides, Sanofi Genzyme; Contracted Research: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Precision BioSciences, Sutro Biopharma, TeneoBio.
MODERATOR — Robert Z Orlowski, MD, PhD – Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Consulting Agreement: STATinMED; Contracted Research: BioTheryX Inc, CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals North America Inc; Ownership Interest: Asylia Therapeutics Inc (founder, patents, equity).
THE UNIVERSITY OF NEBRASKA MEDICAL CENTER (UNMC) and RESEARCH TO PRACTICE (RTP) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — The below planning committee members have nothing to disclose: Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC — RTP Reviewer, and Kathryn Ault Ziel, PhD — RTP Staff and Planner.
Supporters
This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Oncopeptides and Takeda Oncology.
Location
Fairmont Orchid
1 North Kaniku Drive
Kohala Coast, HI 96743
Hotel Phone: (808) 885 2000
Meeting Room
Grande Ballroom (Lobby Level)
Directions
The Fairmont Orchid is the host hotel for the 2021 Pan Pacific Lymphoma Conference.
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of multiple myeloma.
There is no fee to participate in this satellite symposium program or live webcast of this event.
Registration for in-person symposium
In order to attend the in-person symposia event you must be registered for the 2021 Pan Pacific Lymphoma Conference.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
